Completed

L-5-Hydroxy-Tryptophan-Related Eosinophilia-Myalgia Syndrome (EMS): Clinical Patient Evaluation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Behavior+16

+ Mental Disorders

+ Behavioral Symptoms

See all eligibility criteria
How is the trial designed

Observational
Study Start: July 1999
See protocol details

Summary

Principal SponsorNational Institute of Mental Health (NIMH)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Study start date: July 1, 1999

Actual date on which the first participant was enrolled.

The L-tryptophan-related eosinophilia myalgia syndrome (EMS), characterized by eosinophilia, myalgias, myositis, scleroderma-like skin fibrosis and fasciitis, occurred in 1989 in over 1500 patients who had ingested L-tryptophan for sleep disturbances and depression. The identical clinical syndrome has also occurred in subjects ingesting L-5-hydroxytryptophan (L-5-HTP). Recently, a letter to Nature Medicine reported the presence of an impurity in 6 out of 6 samples of L-5-HTP obtained randomly at health food stores. This impurity appears to be the same as the one identified in material ingested by a family (mother and 2 babies) who had developed an EMS-like syndrome after ingesting L-5-HTP. Although there have been no definite new cases of L-5-HTP-related EMS, the FDA is currently investigating unconfirmed reports of possible new cases.

NCT00001918
Principal SponsorNational Institute of Mental Health (NIMH)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

BehaviorMental DisordersBehavioral SymptomsEosinophiliaHematologic DiseasesHemic and Lymphatic DiseasesLeukocyte DisordersMuscular DiseasesMusculoskeletal DiseasesNervous System DiseasesNeurologic ManifestationsNeuromuscular DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurobehavioral ManifestationsDepressionMemory DisordersSleep Wake DisordersEosinophilia-Myalgia Syndrome

Criteria

Patients must be at least 18 years of age. Patients newly diagnosed with eosinophilia and myalgia, and who ingested L-5-HTP. Subjects will be defined as having 5-L-HTP related EMS according to the diagnostic criteria originally established by the CDC for diagnosis of L-tyrptophan-related EMS.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Institute of Mental Health (NIMH)

Bethesda, United StatesOpen National Institute of Mental Health (NIMH) in Google Maps
CompletedOne Study Center